<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03362814</url>
  </required_header>
  <id_info>
    <org_study_id>ASC-ASC16-II/III-CTP-1-01</org_study_id>
    <nct_id>NCT03362814</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.</brief_title>
  <official_title>A Phase2/3, Multi-center, Randomized, Double-blind, Placebo-parallel Controlled Study to Investigate the Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Genotype 1 Infected Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascletis Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascletis Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of Ravidasvir in combination
      with Danoprevir/r and ribavirin(RBV) by sustain virologic response 12 (SVR12), in
      treatment-naive, non-cirrhotic, chronic hepatitis C genotype 1 infected patients.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">September 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants achieving sustained Virologic response 12 weeks after EOT</measure>
    <time_frame>Post treatment Week 12</time_frame>
    <description>SVR12 was defined as HCV RNA &lt; the lower limit of quantitation (LLOQ) 12 weeks after cessation of therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events leading to permanent discontinuation of study drug</measure>
    <time_frame>baseline to week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants achieving sustained Virologic response 4 weeks after EOT</measure>
    <time_frame>Post treatment Week 4</time_frame>
    <description>SVR4 was defined as HCV RNA &lt; the lower limit of quantitation (LLOQ) 4 weeks after cessation of therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants achieving sustained Virologic response 24 weeks after EOT</measure>
    <time_frame>Post treatment Week 24</time_frame>
    <description>SVR24 was defined as HCV RNA &lt; the lower limit of quantitation (LLOQ) 24 weeks after cessation of therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quatitation change of HCV RNA compared to baseline after treatment</measure>
    <time_frame>Baseline to week 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with viral breakthrough</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Viral breakthrough was defined as HCV RNA ≥LLOQ after having previously had HCV RNA&lt; LLOQ while receiving treatment, confirmed with 2 consecutive values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with viral relapse</measure>
    <time_frame>End of treatment to post-treatment week 24</time_frame>
    <description>Viral relapse was defined as HCV RNA ≥LLOQ during the post treatment period having achieved HCV RNA &lt; LLOQ at end of treatment, confirmed with 2 consecutive values.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">425</enrollment>
  <condition>HCV</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ravidasvir + Danoprevir + Ritonavir + Ribavirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ravidasvir placebo + Danoprevir placebo + Ritonavir placebo + Ribavirin placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ravidasvir</intervention_name>
    <description>Ravidasvir 200mg tablet administered orally once daily</description>
    <arm_group_label>Experimental Group</arm_group_label>
    <other_name>ASC16</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danoprevir</intervention_name>
    <description>Danoprevir 100mg tablet administered orally twice daily</description>
    <arm_group_label>Experimental Group</arm_group_label>
    <other_name>ASC08</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>Ritonavir 100mg tablet administered orally twice daily</description>
    <arm_group_label>Experimental Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin 100 MG</intervention_name>
    <description>Ribavirin tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations(&lt;75kg = 1000mg and ≥75kg = 1200mg)</description>
    <arm_group_label>Experimental Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ravidasvir Placebo</intervention_name>
    <description>Ravidasvir Placebo tablet administered orally once daily</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danoprevir Placebo</intervention_name>
    <description>Danoprevir Placebo tablet administered orally twice daily</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir Placebo</intervention_name>
    <description>Ritonavir Placebo tablet administered orally twice daily</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin Placebo</intervention_name>
    <description>Ribavirin Placebo tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations(&lt;75kg = 5 tablets and ≥75kg = 6 tablets)</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infection with Chronic hepatitis C genotype 1confirmed at screening;

          -  Anti-HCV positive；

          -  HCV RNA ≥1 × 10000IU / mL;

          -  Not treated with interferon and / or any other direct-acting antiviral (DAA) drug;

          -  Non-cirrhotic;

          -  Voluntarily sign informed consent.

        Exclusion Criteria:

          -  HCV genotypes 2 to 7 or undetectable HCV genotype or mixed HCV genotype;

          -  Fibroscan detection result &gt; 12.9kPa or Histopathological examination result of
             patients is with cirrhosis;

          -  Past or existing evidence of the presence of non-HCV-induced chronic liver disease;

          -  Previous history of hepatocellular carcinoma, or suspected hepatocellular carcinoma
             found prior to screening, or suspected abdominal hepatoblastoma at screening or
             AFP&gt;100ng/mL;

          -  Anti-HAV (IgM) 、HBsAg 、anti-HEV (IgM) or anti-HIV is positive;

          -  BMI&lt;18 or≥30 kg/m2;

          -  ANC&lt;1.5×109/L、PLT&lt;100×109/L、HB&lt;110g/L（female）or&lt;120g/L（male）；INR&gt;1.5；ALT or
             AST≥5*ULN；TBIL≥2*ULN（DBIL≥ 35%TBIL）；Cr≥1.5*ULN;

          -  Others as specified in detailed protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yahong Chen, Master</last_name>
    <role>Study Director</role>
    <affiliation>Ascletis Pharmaceuticals Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University People's hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2017</study_first_submitted>
  <study_first_submitted_qc>December 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2017</study_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>Ravidasvir</keyword>
  <keyword>SVR12</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lactams</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

